%3Aformat(webp)&w=3840&q=75)
Västra Hamnen initiates coverage of CombiGene
2024-06-20
The prospects for gene therapies have raised the hopes and expectations of patients, healthcare professionals and investors in the life sciences industry. The first therapies have been approved, and more are on the way. Gene therapies are expected to take off in the 2020s as global pharmaceutical companies compete to position themselves in a field with great medical and commercial potential. Swedish gene therapy specialist CombiGene focuses on discovering promising projects, developing them into the clinical phase and out-licensing them after achieving preclinical proof of concept. Our risk-adjusted DCF model indicates a fair value of SEK 12.19 per share
Read our initial analysis below.
